This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Article
Ahmed Elgazzar
Banha University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
EDITORIAL NOTE:
Research Square withdrew this preprint on 14 July, 2021 due to an expression of concern communicated directly to our staff. These concerns are now under formal investigation.
(note updated 19 July, 2021)
Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts.
Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with mild/moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxychloroquine plus standard care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standar care; Group IV: 100 patients with Severe COVID-19 infection received hydroxychloroquine plus standard care. Routine laboratory investigations and rT-PCR, were reported before and after initiation of treatment. Group V stick to personal protective measures (PPM ) plus Ivermectin o.4mg / kg on empty stomach to be repeated after one week, and group VI stick to PPM only .Both groups V&VI were followed for two weeks ..
Results: Patients received ivermectin early reported substantial recovery of laboratory investigations; and significant reduction in rT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (99% & 0.0%, respectively) and group III (94% & 2.0% respectively) versus hydroxychloroquine plus standard care treated groups; group II (74% and 4%, respectively) and group IV (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group when used as a prophylaxis.
Conclusion: Early addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality,rt-PCR conversion days , recovery time hospital stay compared to Hydroxychloroquine plus standard care. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm
Keywords
Ivermectin, COVID-19, Hydroxychloroquine
Figure 1
There is NO Competing Interest.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
Community comments: 19
Version 3
Posted 28 Dec, 2020
Community comments: 24
Community comments: 55
Community comments: 6
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Article
Ahmed Elgazzar
Banha University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
The most recent version of this article is available here.
Community comments: 19
Version 3
Posted 28 Dec, 2020
Community comments: 24
Community comments: 55
Community comments: 6
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
EDITORIAL NOTE:
Research Square withdrew this preprint on 14 July, 2021 due to an expression of concern communicated directly to our staff. These concerns are now under formal investigation.
(note updated 19 July, 2021)
Background: Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts.
Subject and methods: 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; Group I: 100 patients with mild/moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; Group II: 100 patients with mild/moderate COVID-19 infection received hydroxychloroquine plus standard care; Group III: 100 patients with severe COVID-19 infection received Ivermectin plus standar care; Group IV: 100 patients with Severe COVID-19 infection received hydroxychloroquine plus standard care. Routine laboratory investigations and rT-PCR, were reported before and after initiation of treatment. Group V stick to personal protective measures (PPM ) plus Ivermectin o.4mg / kg on empty stomach to be repeated after one week, and group VI stick to PPM only .Both groups V&VI were followed for two weeks ..
Results: Patients received ivermectin early reported substantial recovery of laboratory investigations; and significant reduction in rT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (99% & 0.0%, respectively) and group III (94% & 2.0% respectively) versus hydroxychloroquine plus standard care treated groups; group II (74% and 4%, respectively) and group IV (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group when used as a prophylaxis.
Conclusion: Early addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality,rt-PCR conversion days , recovery time hospital stay compared to Hydroxychloroquine plus standard care. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm
Figure 1
There is NO Competing Interest.
Loading...